Biotech
43 stories covering biotech — fund closes, LP allocations, regulatory filings, deal flow, and fundraising signals from PipelineRoad's editorial team.
IPO Pipeline Thaws for Venture-Backed Startups in AI and Clean Energy
Recent S-1 filings show increased IPO activity among venture-backed companies in semiconductors, nuclear power, biotech, and space tech, according to Crunchbase News.
Venture-Backed IPOs Surge in AI, Clean Energy, and Biotech
Recent public S-1 filings show venture-backed startups in semiconductors, nuclear power, geothermal energy, biotech, and space tech pursuing IPOs, according to Crunchbase News.
Venture-Backed Startups File for IPOs in Semiconductors, Clean Energy, and Biotech
Recent public S-1 filings from venture-backed companies in semiconductors, nuclear power, geothermal energy, biotech, and space tech signal increased IPO activity, according to Crunchbase News.
Venture-Backed Startups File for IPOs in AI, Semiconductors, and Clean Energy
Recent S-1 filings show venture-backed companies in semiconductors, nuclear power, biotech, and space tech pursuing IPOs, according to Crunchbase News.
Venture-Backed Startups Increase IPO Filings in Key Sectors
Recent weeks have featured numerous public S-1 filings from venture-backed companies in semiconductors, nuclear power, geothermal energy, biotech, and space and defense tech.
Venture-Backed Startups Accelerate IPO Filings in Key Sectors
Recent S-1 filings show venture-backed companies in semiconductors, clean energy, biotech, and space tech pursuing public offerings, according to Crunchbase News.
Venture-Backed Startups File for IPOs in AI, Energy, and Biotech
Recent S-1 filings by venture-backed companies in semiconductors, nuclear power, geothermal energy, biotech, and space defense signal growing IPO activity.
Aligos Therapeutics Enters Exclusive License Deal with Amoytop for HBV Drug in Greater China
Aligos Therapeutics has signed an exclusive agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium for chronic hepatitis B in Greater China, including upfront payments
Mesoblast Acquires Exclusive License to CAR Technology Platform
Mesoblast Limited announced on April 14, 2026, its acquisition of an exclusive worldwide license to a patented CAR technology for enhancing MSC products, according to GlobeNewswire PE.
Gilead Acquires Tubulis for $3.15 Billion to Enhance Drug Pipeline
Gilead Sciences announces a $3.15 billion acquisition of Tubulis, a cancer biotech firm, to expand its oncology and other therapeutic capabilities.
Gilead Acquires Tubulis for $3.15 Billion to Enhance Pipeline
Gilead Sciences announced a $3.15 billion acquisition of Tubulis, a cancer biotech with ADC technologies, to expand beyond oncology.
Petrichor Appoints Paul J. Sekhri as Operating Partner
Petrichor, a growth-focused healthcare and life sciences investment firm, has appointed Paul J. Sekhri as Operating Partner, drawing on his over 35 years of experience in biotech and pharmaceuticals.
Neurocrine Acquires Soleno for $2.9 Billion to Add PWS Drug
Neurocrine Biosciences expands its rare disease portfolio through a $2.9 billion acquisition of Soleno Therapeutics, gaining Vykat XR for Prader-Willi syndrome.
Neurocrine Acquires Soleno for $2.9 Billion to Gain Vykat XR
Neurocrine Biosciences expands its rare disease portfolio by acquiring Soleno Therapeutics for $2.9 billion, adding Vykat XR for Prader-Willi syndrome.
AC Immune Amends Morphomer Tau Agreement with Lilly
AC Immune SA announced an amendment to its 2018 license and collaboration agreement with Eli Lilly for Tau aggregation inhibitors, including a CHF10 million upfront payment.
Top 10 US Startup Funding Rounds This Week in Defense and Tech
Crunchbase News reports the week's largest funding rounds for US startups, led by a $1.75 billion Series D for defense tech firm Saronic.
Transgene and NEC Bio Sign License Agreement for TG4050 Development
Transgene and NEC Bio have signed a license agreement to advance TG4050 for head and neck cancer, involving payments in shares and cash.
Transgene and NEC Bio Sign License for TG4050 Development
Transgene and NEC Bio have signed a license agreement to advance TG4050 for HPV-negative head and neck cancer treatment, including financial payments.
Transgene and NEC Bio Sign License for TG4050 Development in Head and Neck Cancers
Transgene and NEC Bio announced a license agreement on April 2, 2026, for advancing TG4050, a personalized vaccine for HPV-negative head and neck cancers, including financial payments to NEC.
Transgene and NEC Bio Sign License for TG4050 in Head and Neck Cancer
Transgene and NEC Bio have signed a license agreement to advance TG4050's development for resected HPV-negative head and neck cancer, including financial terms like a €2.5 million technology access fe
Axsome Therapeutics Acquires Balipodect for Schizophrenia Treatment
Axsome Therapeutics has obtained exclusive global rights to balipodect, a selective PDE10A inhibitor, from Takeda for developing treatments for schizophrenia and other neuropsychiatric conditions.
BriaCell and BriaPro Close Asset Purchase for Soluble CD80 License
BriaCell Therapeutics Corp. and BriaPro Therapeutics Corp. completed an asset purchase transaction for the exclusive Soluble CD80 license, as announced on March 31, 2026.
BriaCell and BriaPro Complete Asset Purchase for Soluble CD80 License
BriaCell Therapeutics Corp. and BriaPro Therapeutics Corp. announced the closing of an asset purchase transaction for an exclusive cancer treatment license, involving share issuance and a credit facil
NorthStrive Biosciences Amends Licensing Agreement with MOA Life Plus
PMGC Holdings subsidiary NorthStrive Biosciences updates milestones for EL-32 and EL-22 in licensing deal with Korean biotech firm MOA Life Plus, as announced on March 27, 2026.
NurExone Announces Sublicense Agreement for U.S. Subsidiary
NurExone Biologic Inc. grants sublicense rights to Exo-Top Inc. to support U.S. manufacturing and development of exosome therapies.
NurExone Biologic Inc. Announces Sublicense Agreement for U.S. Manufacturing
NurExone Biologic Inc. grants sublicense rights to its U.S. subsidiary Exo-Top Inc. to support manufacturing and development of exosome therapies, as announced on March 26, 2026.
20/20 BioLabs Secures Exclusive U.S. License with ROKIT Healthcare for CKD Technology
20/20 BioLabs announces a licensing agreement with ROKIT Healthcare to integrate CKD prediction into its longevity platform, as per GlobeNewswire PE.
20/20 BioLabs Announces Exclusive U.S. License with ROKIT Healthcare
20/20 BioLabs has entered an exclusive U.S. license agreement with ROKIT Healthcare to integrate CKD prediction technology into its Longevity Test Program, as per a recent announcement.
Yatiri Bio Secures Exclusive Option for Denfivontinib Licensing from Oscotec
Yatiri Bio announced an exclusive global option to license denfivontinib from Oscotec for AML treatment, utilizing its AI-driven platform.
Red Light Holland Engages Kala Bio's AI for PEX010 Development
Red Light Holland has engaged Kala Bio's Researgency.ai platform to advance the clinical development of Filament's PEX010 psilocybin drug candidate, as announced on March 18, 2026.
Red Light Holland Engages Kala Bio’s AI for PEX010 Psilocybin Development
Red Light Holland has engaged Kala Bio’s Researgency.ai platform to advance the clinical development of Filament’s PEX010 botanical psilocybin drug candidate, as per a March 18, 2026 announcement.
VVMF Enters Licensing Agreement with OXB for Viral Vector Platforms
Australia's Viral Vector Manufacturing Facility signs a licensing deal with OXB for access to advanced viral vector technologies, announced on March 18, 2026.
PolyPid Receives $4.3 Million FDA PDUFA Fee Waiver for D-PLEX100 NDA
PolyPid Ltd. announced on March 17, 2026, that the FDA granted a $4.3 million PDUFA fee waiver for D-PLEX100's New Drug Application, aiding commercialization efforts.
PolyPid Secures FDA PDUFA Fee Waiver for D-PLEX100 NDA
PolyPid Ltd. received a $4.3 million PDUFA fee waiver from the FDA for its D-PLEX100 New Drug Application, supporting commercialization preparations.
Zevra Therapeutics Sells SDX Portfolio to Commave for $50 Million
Zevra Therapeutics announced the sale of its SDX portfolio, including AZSTARYS and KP1077, to Commave Therapeutics for $50 million on March 16, 2026, settling a prior lawsuit.
KOMO Biosciences Grants License to Syngenta for Maize Genome Tech
KOMO Biosciences has granted Syngenta a research license to evaluate its KOMbine platform for precision genome modification in maize, as announced on March 11, 2026.
Series B Funding Diversifies and Grows in 2026
Crunchbase data shows U.S. Series B funding increasing after 2023 lows, with diversified sectors and larger average round sizes in 2026.
Premier Graphene Advances Industrial Hemp Import Permits in Mexico
Premier Graphene Inc. announces its affiliate has progressed industrial hemp import permits and licensing, enabling operations in Mexico.
KALA BIO Announces AI Platform for Biotech and Pharma Sector
KALA BIO enters agreement with Younet AI to develop an on-premises AI infrastructure for secure biotech data analysis, addressing industry challenges.
Hopewell Therapeutics Sublicenses LNPs to Foxcroft for Cancer Vaccine Development
Hopewell Therapeutics grants a global sublicense of its tissue-targeting LNPs to Foxcroft Therapeutics for novel cancer vaccines, including financial terms and planned collaborations.
Candid Therapeutics Merges with Rallybio and Raises $505 Million
Candid Therapeutics announces a reverse merger with Rallybio and $505 million in private financing to advance its autoimmune drug pipeline.
Science Corp. Series C Signals Deeptech LP Interest Amid Market Recovery
Neuralink alumni startup raises $230M Series C, highlighting renewed institutional appetite for capital-intensive biotech ventures.
March Opens With $500M+ Rounds in Space Tech and AI Infrastructure
Three mega-rounds above $500 million signal renewed LP appetite for capital-intensive sectors as Q1 2024 venture activity accelerates.
